Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme gets patent and launches bypass instruments

This article was originally published in Clinica

Executive Summary

Genzyme General Division, the largest division of US biotech company Genzyme, has been issued a US patent for its new mutation detection technology. Multiple Allele-Specific Diagnostic Assay (MASDA) is the first technology to allow simultaneous analysis of hundreds of DNA samples for more than 100 mutations on one or more genes in a single test. MASDA uses a two-step approach. In the first step, samples that are negative for certain mutations are eliminated. In the second step, specific mutations are identified in positive samples.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT084504

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel